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a	multikinase	 inhibitor,	was	 the	 first	 treatment	 to	 show	a	 survival	




who	are	 ineligible	 for	 loco‐regional	 treatment	and	have	preserved	
(Child‐Pugh	A)	liver	function.
However,	 there	 is	 significant	heterogeneity	 in	outcomes	 in	pa‐
tient	 treated	 with	 sorafenib	 with	 an	 OS	 ranging	 from	 <3	 months	




The	variety	 in	survival	 is	 inadequately	captured	by	 the	currently	















ascites)	 or	 are	 not	 commonly	 available	 (ie	 Des‐gamma‐carboxypro‐







and	tested	 in	an	 independent	dataset.	These	models	 for	overall	 survival	 (OS)	were	
then	compared	with	existing	prognostic	models.
Results: The	PROSASH	model	was	validated	 in	445	patients,	 showing	clear	differ‐
ences	between	 the	 four	 risk	groups	 (OS	16.9‐4.6	months).	A	 total	of	920	patients	
(n	=	615	in	training	set,	n	=	305	in	validation	set)	were	available	to	develop	PROSASH‐















cinoma)	can	be	 treated	with	sorafenib	 to	expand	 their	
life	expectancy,	but	the	prognosis	with	this	drug	varies	
between	patients.
•	 In	 this	 large	 international	study,	we	tested	and	further	
improved	 a	 statistical	method	 that	 allows	 clinicians	 to	
estimate	the	survival	chances	of	an	individual	patient.
•	 This	 facilitates	 the	 communication	 with	 the	 patient	
when	 considering	 this	 treatment	 and	will	 help	 further	
research	to	find	better	drugs.


















tice.	 Subsequently,	 PROSASH,	 the	 improved	 model	 (PROSASH‐II)	
and	 existing	 prognostic	 models	 were	 compared	 to	 determine	 the	
utility	for	clinicians	to	predict	the	survival	of	these	patients.
2  | MATERIAL S AND METHODS
2.1 | Study population
Patients	 with	 HCC	 treated	 with	 sorafenib	 were	 recruited	 consecu‐














2.2 | Data collection and outcomes
Commonly	 available	 clinical,	 imaging	 and	 serum	 variables	 prior	 to	
sorafenib	 treatment	 were	 collected	 by	 members	 of	 the	 research	
team.	Imaging	parameters	were	obtained	from	the	most	recent	radi‐
ological	imaging	prior	to	first	dose	of	sorafenib.	Radiological	staging	
included	 a	 multiphasic	 contrast‐enhanced	 computed	 tomography	








BCLC	 staging	 system,	 Child‐Pugh	 classification,	 albumin‐bilirubin	
(ALBI)	grade,30	Japan	Integrated	Staging	(JIS)	score,31	hepatoma	ar‐
terial‐embolization	prognostic	(HAP)32	and	the	Sorafenib	Advanced	
HCC	Prognostic	 (SAP)	 score.18	With	 the	exception	of	BCLC	 stage	
and	 Child‐Pugh	 classification,	 which	 are	 commonly	 used	 in	 daily	
practice	and	were	coded	by	the	individual	investigators,	all	prognos‐
tic scores were calculated using the raw data.
2.3 | Statistical methods
Continuous variables were described as means with standard de‐





P	 <	 .05	was	 considered	 statistically	 significant.	 Statistical	 analysis	
was	performed	using	SPSS	Statistics	for	Windows	Version	24.0	(IBM	
Corp)	and	STATA/SE	14.1	(StataCorp).




set	 and	 the	 largest	 independent	 dataset	 (Bordeaux)	 was	 used	 as	
an	external	validation	set.	Baseline	variables	 that	were	considered	






rameters that were missing at random in the training dataset.33,34 







were	 reported	with	 hazard	 ratio	 (HR)	 and	 corresponding	P values. 
The	multivariable	model	was	 built	 using	 a	 stepwise	 forward	 selec‐
tion	procedure	of	variables	significant	at	the	5%	level.	The	model	was	
reported	according	to	the	TRIPOD	guidelines38	as	well	as	tested,	op‐
timized and validated using the methods described by Royston and 






A	 linear	 predictor	 was	 derived	 using	 the	 coefficients	 of	 the	
model	 variables.	 Four	 risk	 groups	were	generated	by	 applying	 the	
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previously	suggested	cut‐offs	at	the	16th,	50th	and	84th	centiles	of	
the	training	set's	linear	predictor.39 The model, including the linear 
predictor	and	the	centile‐based	risk	group	stratification,	was	applied	
to	the	external	validation	set.
The	 calibration	 of	 survival	 prediction	was	 visually	 assessed	 by	
comparing	the	similarity	between	the	observed	and	predicted	sur‐
vival curves in both the training and validation set. The observed and 










nase	 (AST)’	 which	 was	 not	 available	 in	 the	 Rennes	 (training)	 and	
Bordeaux	(validation)	datasets.	Therefore,	model	comparisons	were	
performed	in	three	subgroups	of	patients:





















tween	February	 2003	 and	December	2016	were	 identified	 for	 this	
study.	Of	these,	21	patients	(2%)	were	excluded	because	they	received	




baseline	 characteristics	 of	 both	 cohorts	 are	 summarized	 in	Table	1.	
Both	cohorts	had	similar	baseline	 features	except	 that	 in	 the	exter‐











available	 owing	 to	missing	 AST	 (Table	 S1).	With	 the	 exception	 of	
risk	 group	 2	 vs	 1	 (HR	1.35,	 0.94‐1.92,	P	 =	 .102),	 there	were	 clear	
survival	differences	between	the	four	risk	groups	with	a	median	OS	
ranging	from	16.9	to	4.6	months	 (Figure	1)	 in	 risk	groups	1	and	4,	
respectively.




showed	 that	 albumin,	 Ln(bilirubin),	 ECOG	PS,	macrovascular	 inva‐
sion,	 extrahepatic	 spread,	 largest	 tumour	 size,	 number	 of	 liver	 le‐
sions,	Ln(AFP)	and	receiving	prior	HCC	treatments	were	associated	
with	OS	(Table	S2).
The	 stepwise	 multivariable	 regression	 identified	 albumin,	
Ln(bilirubin),	 macrovascular	 invasion,	 extrahepatic	 spread,	 largest	
tumour	 size	 and	Ln(AFP)	 as	 statistically	 significant	prognostic	 fac‐
















(Table	 S3)	 and	 imputed	 data	 showed	 very	 similar	 coefficients	 and	
P	values,	indicating	that	the	model	was	not	greatly	impacted	by	the	
imputation	of	missing	data.
Using	 the	 centile‐based	 cut‐points,	 four	 risk	 groups	were	 cre‐
ated:	 ≤−0.0760	 (risk	 group	 1),	 >−0.0760	 to	 ≤0.355	 (risk	 group	 2),	
>0.355	to	≤0.858	(risk	group	3)	and	>0.858	(risk	group	4).
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TA B L E  1  Baseline	characteristics
Variables
Entire cohort Training‐set External validation
P valuen = 920 n = 615 n = 305
Demographics
Age,	y	(SD) 65	(10.5) 64	(10.8) 66	(9.5) .003
Male	sex	(%) 787	(86) 512	(83) 275	(90) .005
Liver	disease
Aetiology	(%,	multiple	possible)
HBV 94	(10) 77	(13) 17	(6) .001
HCV 153	(17) 86	(14) 67	(22) .002
Alcohol 407	(44) 213	(35) 194	(64) <.001
Unknown/Other 407	(44) 263	(43) 64	(21) <.001
Child‐Pugh	class	(%)
A 747	(85) 507	(87) 240	(79) <.001
B 133	(15) 73	(13) 60	(20)  
C 4	(<1) 0	(0) 4	(1)  
Tumour	parameters
ECOG	PS	(%)
0 477	(52) 279	(45) 198	(65) <.001
1 388	(42) 294	(48) 94	(31)  
2 55	(6) 42	(7) 13	(4)  
Number	of	liver	lesions	(%)
1 229	(25) 135	(22) 94	(32) <.001
2‐3 205	(23) 169	(28) 36	(12)  
>3 468	(52) >3	(50) 163	(56)  
Largest	tumour	size,	mm	(IQR) 65	(37‐100) 65	(37‐100) 64	(36‐100) .593
Macrovascular	invasion	(%) 348	(38) 223	(36) 125	(41) .170
Extrahepatic	spread	(%) 418	(46) 305	(50) 113	(37) <.001
BCLC	stage	(%)
A 9	(1) 5	(1) 4	(1) .032
B 220	(24) 155	(25) 65	(21)  
C 684	(74) 453	(74) 231	(76)  
D 6	(<1) 1	(<1) 5	(2)  
Prior	treatments	(%)
Yes,	received	prior	treatment 467	(51) 308	(50) 159	(52) .558
No,	sorafenib	was	first	treatment 453	(49) 307	(50) 146	(48)  
Serum	tests
AFP,	ng/mL	(IQR) 141	(8‐2574) 127	(10‐2005) 184	(7‐4500) .239
Albumin,	g/L	(SD) 37	(5.7) 38	(5.3) 35	(5.8) <.001
Bilirubin,	µmol/L	(IQR) 15	(10‐24) 15	(10‐22) 17	(12‐28) <.001
AST,	U/L	(IQR) 67	(107) 67	(107) N/A N/A
Creatinine,	µmol/l	(IQR) 73	(61‐88) 75	(62‐90) 69	(58‐81) <.001
Survival	outcomes
Death	(%) 832	(90) 559	(91) 273	(90) .501
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To	simplify	individual	survival	prediction,	the	calculation	for	the	
linear	predictor	and	risk	groups	was	incorporated	in	an	online	cal‐




the largest tumour measuring 5.9 cm with macrovascular invasion, 
but	without	extrahepatic	spread,	will	have	a	predicted	survival	of	
87%, 70%, 44% and 19% and 9% at 3, 6, 12, 24 and 36 months, 
respectively.	 The	 equations	 for	 these	 predictions	 are	 detailed	 in	
Appendix	S1.






































Risk group 1 42 16.9 (13.4-20.0) 1 Reference
Risk group 2 154 10.4 (8.4-11.8) 1.35 (0.94-1.92) .102
Risk group 3 176 6.7 (5.9-8.4) 2.16 (1.52-3.07) <.001
Risk group 4 73 4.6 (3.0-5.6) 3.20 (2.15-4.77) <.001
TA B L E  2  Multivariable	flexible	parametric	regression	on	
imputed	training	set	data
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to	 risk	 group	1	 and	only	10	 (13.4%)	 to	 risk	 group	2.	 There	was	 a	
trend	 towards	 a	 poorer	 survival	 across	 risk	 groups	 2	 to	 4	with	 a	
median	OS	of	13.4,	5.4	and	3.1	months,	respectively.	The	difference	
between	 risk	groups	2	and	3	was	not	 significant	owing	 to	 limited	
patient	numbers	(HR	1.98,	0.97‐4.04,	P	=	.062).	There	were	statisti‐







set	with	 complete	 data	 (n	 =	 290)	 and	 a	 subgroup	of	 438	patients	
with	 complete	 data	 for	 all	 prognostic	 models.	 Across	 the	 various	











the	 currently	 available	 models.	 Likewise,	 the	 PROSASH‐II	 had	 a	
lower	AIC	(1684)	which	indicated	a	better	goodness	of	fit.
In	 the	 validation	 set,	 the	 PROSASH‐II	 model	 had	 a	 higher	 C‐
index	(0.68,	95%	CI	0.65‐0.72)	and	lower	AIC	(828)	than	commonly	
used	scores	 such	as	BCLC	and	Child‐Pugh.	 It	 also	had	 the	highest	
R2D	 (0.16,	95%	CI	0.08‐0.24)	of	all	tested	models,	reflecting	better	
explained	variation.	However,	 the	model	 appeared	 to	have	a	 simi‐
lar	prognostic	performance	as	 the	HAP	and	SAP	scores,	 the	 latter	
showing	a	slightly	higher	C‐index	(0.69,	95%	CI	0.66‐0.72)	and	lower	
AIC	(817)	than	the	PROSASH‐II	model.
F I G U R E  2  Overall	survival	according	to	the	PROSASH‐II	risk	
groups	in	the	training	(A)	and	validation	(B)	set	with	95%	confidence	
intervals
F I G U R E  3  Calibration	plot	of	the	predicted	(dotted	line)	and	
observed	(solid	line)	of	the	overall	survival	according	to	PROSASH‐
II	risk	groups	in	the	training	(A)	and	validation	(B)	set
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dated	and	optimized	 (PROSASH‐II)	 in	 routine	clinical	practice.	The	
PROSASH‐II	model,	which	 uses	 fewer	 and	more	objective	 param‐
eters	and	performed	at	least	as	good	as	PROSASH,	offers	individual‐








sification	 and	 inter‐observer	 variability,9	 whereas	 the	 prognostic	
value	of	BCLC	staging	for	patients	treated	with	the	same	modality	
is	 low.	To	optimize	cost‐effectiveness	and	aid	clinicians	 in	 survival	
prediction	 and	 clinical	 decision‐making,	 several	 other	 prognostic	
models	 have	 been	 proposed	 to	 stratify	 these	 patients	 (Table	 6).	





We	 were	 able	 to	 compare	 eight	 different	 prognostic	 models:	





















































































































































































































































































































































































































































































































































































































































































































































































































F I G U R E  4  Calibration	plot	of	the	predicted	(dotted	line)	
and	observed	(solid	line)	of	the	overall	survival	according	to	the	
PROSASH‐II	risk	groups	(1‐4)	in	all	patients
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proposed	PROSASH‐II	model	 (Table	6).	All	 tested	models	 included	




predictive	 parameters	 that	were	 associated	with	 increased	 benefit	






dance	with	 prior	 studies,9,48,49	 we	 showed	 that	 despite	 using	 less	
parameters,	 ALBI	 has	 a	 better	 discrimination	 than	 the	Child‐Pugh	
classification.
Although	 initially	 developed	 to	 stratify	 HCC	 patients	 treated	
with	TACE,	 the	HAP	score	 showed	 that	 a	 further	 improvement	of	
predictive	accuracy	is	possible	by	combining	liver	function	(albumin,	







neither	 the	 SAP	 nor	 HAP	 score	 offer	 individualized	 survival	 pre‐
diction	 and	 do	 not	 incorporate	 predictors	 of	 improved	 sorafenib	
benefit.
Both	 the	 PROSASH	 and	 PROSASH‐II	 models	 offer	 indi‐
vidualized	 survival	 prediction	 and	 propose	 an	 externally	 vali‐
dated	 four‐tier	 subgroup	 classification	 with	 a	 median	 survival	
of	 17‐10‐7‐5	months	 and	 19‐11‐7‐3	months,	 for	 risk	 groups	 1‐4,	
respectively.	The	PROSASH	incorporated	albumin,	AFP,	AST,	cre‐
atinine,	 age,	 extrahepatic	 spread,	macrovascular	 invasion,	 ECOG	
PS	and	disease	aetiology	 (nine	parameters	 in	 total),	whereas	 the	
PROSASH‐II	 incorporated	 albumin,	 AFP,	 extrahepatic	 spread,	
macrovascular	 invasion,	 tumour	 size	 and	 bilirubin	 (six	 parame‐
ters	 in	 total).	 It	 is	 inevitable	 that	different	studies	with	different	
datasets	 lead	 to	 (slightly)	 different	prognostic	models.	However,	
despite	the	different	origins	(clinical	trial	vs	daily	practice),	there	
is	 significant	 overlap	 in	 the	 PROSASH‐I	 and	 ‐II	 variables	 which	
suggests that these variables are stable and clinically relevant. 
As	 pointed	 out	 by	 several	 statistical	 experts,	 there	 is	 no	widely	
agreed	approach	to	build	a	multivariable	prognostic	model	from	a	
TA B L E  4  Comparison	between	of	the	predictive	performance	of	prognostic	models	in	the	training	and	validation	set
Staging system (no. of 
strata)
Imputed training set (n = 615) Complete case validation set (n = 290)
AIC C‐index (IQRb) R2D (95% CI
a) AIC C‐index (95% CIa) R2D (95% CI
a)
PROSASH‐II
Linear	predictor 1684 0.65	(0.64‐0.65) 0.12	(0.08‐0.17) 828 0.68	(0.65‐0.72) 0.16	(0.08‐0.24)
Grouped	(4) 1697 0.64	(0.64‐0.64) 0.12	(0.08‐0.17) 839 0.67	(0.64‐0.70) 0.16	(0.09‐0.25)
PROSASH
Linear	predictor — — — — — —
Grouped	(4) — — — — — —
ALBI
Linear	predictor 1764 0.59	(0.59‐0.59) 0.04	(0.01‐0.06) 867 0.62	(0.58‐0.65) 0.06	(0.03‐0.13)
Grade	(3) 1781 0.56	(0.55‐0.56) 0.03	(<0.01‐0.05) 877 0.58	(0.55‐0.61) 0.05	(0.01‐0.12)
Child‐Pugh	(3) 1782 0.53	(0.53‐0.53) 0.05	(0.01‐0.09) 867 0.58	(0.55‐0.61) 0.11	(0.04‐0.21)
BCLC	(4)c 1785 0.54	(0.52‐0.56) 0.02	(<0.01‐0.06) 885 0.57	(0.55‐0.60) 0.03	(0.01‐0.08)
HAP
Points	(5) 1733 0.60	(0.60‐0.60) 0.08	(0.04‐0.12) 833 0.67	(0.64‐0.70) 0.16	(0.09‐0.25)
Classes	(4) 1738 0.60	(0.60‐0.60) 0.08	(0.04‐0.11) 840 0.66	(0.63‐0.69) 0.14	(0.07‐0.23)
SAP
Points	(5) 1733 0.60	(0.60‐0.61) 0.08	(0.04‐0.12) 817 0.69	(0.66‐0.72) 0.16	(0.09‐0.27)
Classes	(3) 1738 0.59	(0.59‐0.59) 0.09	(0.04‐0.13) 830 0.66	(0.63‐0.69) 0.14	(0.07‐0.23)












available	 in	 centres	 treating	 patients	with	HCC.	 Secondly,	mod‐
els	should	be	widely	validated	and	universally	applicable.	For	this	











tailored	 treatment.	Moreover,	 PROSASH‐II	was	 built	 and	 tested	
on	a	daily	clinical	practice	population	 in	which	 it	will	be	applied.	
Currently,	guidelines	recommend	to	consider	all	patients	with	well‐
preserved	 liver	 function	 (Child‐Pugh‐A)	 who	 are	 unsuitable	 for	
loco‐regional	therapy	for	sorafenib	treatment.	The	clear	subgroup	
survival	 differences	 of	 PROSASH‐II	 risk	 groups	 in	 Child‐Pugh	 A	
patients	show	that	even	in	‘guideline	concordant	patients’	a	more	
individualized	 decision	 is	 possible.	 Patients	 within	 risk	 group	 3	
(median	OS	7‐8	months)	may	have	more	benefit	from	alternative	



















This	 study	 has	 several	 limitations,	 foremost	 the	 retrospective	
design	 and	 its	 inherent	 limitations.	 Owing	 to	missing	 parameters,	
some	previously	 proposed	prognostic	 factors	 (ie	NLR,16,52‐55 body 
composition13,56)	could	not	be	taken	into	account	and	not	all	previ‐
ously	proposed	models	could	be	 included	in	the	comparison	(CLIP,	
NIACE).	Secondly,	 this	 study	was	performed	 in	patients	 treated	 in	
European	countries	 and	 should	be	validated	 in	other	geographical	
areas	(i.e.	Asia).
Despite	over	a	decade	of	sorafenib	usage	and	extensive	studies,	
no	molecular	markers	with	 a	 strong	 association	with	mechanism	of	









radiological	 response	or	 pattern	of	 progression).	 The	more	 recently	









TA B L E  5  Comparison	of	prognostic	models	in	a	complete	case	
population
Staging system (no. 
of strata)
Complete case for all models (n = 438)
AIC C‐index (95% CI*) R2D (95% CI
a)
PROSASH‐II
Linear	predictor 1260 0.63	(0.60‐0.66) 0.10	(0.06‐0.15)
Grouped	(4) 1266 0.62	(0.60‐0.65) 0.10	(0.05‐0.15)
PROSASH
Linear	predictor 1278 0.62	(0.59‐0.65) 0.07	(0.04‐0.11)
Grouped	(4) 1279 0.61	(0.58‐0.64) 0.08	(0.04‐013)
ALBI
Linear	predictor 1303 0.58	(0.55‐0.61) 0.03	(0.01‐0.07)
Grade	(3) 1318 0.54	(0.52‐0.57) 0.02	(<0.01‐0.05)
Child‐Pugh	(3) 1317 0.52	(0.51‐0.54) 0.04	(0.01‐0.07)
BCLC	(4) 1320 0.53	(0.51‐0.56) 0.01	(<0.01‐0.04)
HAP
Points	(5) 1289 0.59	(0.56‐0.62) 0.06	(0.03‐0.11)
Classes	(4) 1292 0.59	(0.56‐0.62) 0.06	(0.03‐0.11)
SAP
Points	(5) 1293 0.59	(0.56‐0.62) 0.05	(0.02‐0.09)
Classes	(3) 1291 0.58	(0.55‐0.61) 0.07	(0.03‐0.13)
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TA B L E  6  Literature	reported	performance	of	prognostic	models	patients	with	HCC	treated	with	sorafenib
Name model
Variables
C‐index Type of cohort (n) ReferencesTumour‐related Liver function Other
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